Trials / Completed
CompletedNCT04640272
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ribomic USA Inc · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RBM-007 | Intravitreal injection |
Timeline
- Start date
- 2020-11-03
- Primary completion
- 2021-11-19
- Completion
- 2021-12-22
- First posted
- 2020-11-23
- Last updated
- 2023-06-08
- Results posted
- 2023-06-08
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04640272. Inclusion in this directory is not an endorsement.